Dronabinol is an orally active cannabinoid which has complex effects on the CNS, including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues. These receptors may play a role in mediating the effects of dronabinol.

MARINOL is a cannabinoid indicated in adults for the treatment of: • Anorexia associated with weight loss in patients with AIDS. • Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Anorexia Associated with Weight Loss in Adult Patients with AIDS:
• The recommended adult starting dosage is 2.5 mg orally twice daily, one hour before lunch and dinner.
• See the full prescribing information for dosage titration to manage adverse reactions and achieve the desired therapeutic effect.

 Nausea and Vomiting Associated with Chemotherapy in Adult Patients Who Failed Conventional Antiemetics:
• The recommended starting dosage is 5 mg/m2, administered 1 to 3 hours prior to the administration of chemotherapy, then every 2 to 4 hours after chemotherapy, for a total of 4 to 6 doses per day. Administer the first dose on an empty stomach at least 30 minutes prior to eating; subsequent doses can be taken without regard to meals.
• See the full prescribing information for dosage titration to manage adverse reactions and achieve the desired therapeutic effect.

Most common adverse reactions (≥3%) are: abdominal pain, dizziness, euphoria, nausea, paranoid reaction, somnolence, thinking abnormal and vomiting.

History of a hypersensitivity reaction to dronabinol or sesame oil.

• Neuropsychiatric Adverse Reactions: May cause psychiatric and cognitive effects and impair mental and/or physical abilities. Avoid use in patients with a psychiatric history. Monitor for symptoms and avoid concomitant use of drugs with similar effects. Inform patients not to operate motor vehicles or other dangerous machinery until they are reasonably certain that MARINOL does not affect them adversely.
• Hemodynamic Instability: Patients with cardiac disorders may experience hypotension, hypertension, syncope, or tachycardia. Avoid concomitant use of drugs with similar effects and monitor for hemodynamic changes after initiating or increasing the dosage of MARINOL. See package insert for complete information.